In Section C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, contributors will get ABBV-744 and ruxolitinib. Members will obtain treatment until illness progression or even the participants are unable to tolerate the study drugs. There might be better treatment load for members During this trial in comparison https://abbv-744combinationtherap68912.get-blogging.com/32552962/not-known-details-about-brd4-inhibition-by-abbv-744-in-cancer-research-studies